HeraMED (ASX:HMD) ROCE % : -48.13% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is HeraMED ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HeraMED's annualized ROCE % for the quarter that ended in Dec. 2024 was -48.13%.

HeraMED ROCE % Historical Data

The historical data trend for HeraMED's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED ROCE % Chart

HeraMED Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-107.73

-283.93

-167.24

-203.77

-226.70

HeraMED Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial								-103.77	-193.22	-378.69	-456.81	-48.13

HeraMED ROCE % Calculation

HeraMED's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-8.593	/	( ( (4.418 - 2.253)	+	(7.08 - 1.664) )	/ 2 )
	=	-8.593	/	( (2.165	+	5.416)	/ 2 )
	=	-8.593	/	3.7905
	=	-226.70 %

HeraMED's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-2.28	/	( ( (6.988 - 2.929)	+	(7.08 - 1.664) )	/ 2 )
	=	-2.28	/	( ( 4.059	+	5.416 )	/ 2 )
	=	-2.28	/	4.7375
	=	-48.13 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

HeraMED (ASX:HMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HeraMED ROCE % Related Terms

Thank you for viewing the detailed overview of HeraMED's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

HeraMED Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (ASX:HMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124

Website

https://www.hera-med.com

HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines